Related Experiment Video
Updated: Jun 5, 2025
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Evaluation of Incurred Subject Period Re-analysis (ISPR) as a Tool to Distinguish Fraudulent Pharmacokinetic Profile
Anders Fuglsang1, Anshul Dogra2, Naveen Sharma2
1Fuglsang Pharma, Aastrupvej 11E, 1.Th, 6100, Haderslev, Denmark. a.fuglsang@ymail.com.
Abstract:
Duplicate pharmacokinetic profiles in bioequivalence trials is an issue which has caused hundreds of retracted marketing authorizations. No formal test for profile duplication exists in spite of the existence of profile comparison algorithms, so defining a threshold that distinguishes a naturally occurring pair from a duplication remains difficult. An idea called ISPR (incurred subject period analysis) was aired in 2023 and is evaluated in this paper along with three new profile comparison methods. ISPR involves analysis of entire PK-profiles within a study. It is shown that when ISPR is combined with appropriate PK-profile comparison methods, the duplicate pairs display a lower score (better similarity) than pair that do not arise out of duplication. Therefore, ISPR may help establish a threshold that distinguishes fraudulent profile pairs from non-fraudulent profile pairs. ISPR therefore may be used as QA tool, serves as a method by which a CRO can -to some extent- show that their studies do not contain duplicates in the primary analysis, and thus also may be a means by which sponsor can argue that their studies are trustworthy, in case the suspicion about duplication arises. This paper does not introduce a formal test for this type of fraud; rather the authors see it as a first moderate step in that direction. Hopefully, if or when ISPR data is submitted to authorities as part of general dossier submission, data will accumulate to the extent that they may be able to develop models that allow formal testing for profile duplication.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
On...
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...